Gabriella Mariani

机构：Tumori Foundation, Fondazione IRCCS Istituto Nazionale dei Tumori · ORCID：0000-0001-7733-3143

发表论文 108 篇 · 总被引 4877 次 · h-index 24

代表论文

• Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study (2022 · Annals of Oncology · 被引 405)
• Spatial predictors of immunotherapy response in triple-negative breast cancer (2023 · Nature · 被引 363)
• Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives (2019 · Critical Reviews in Oncology/Hematology · 被引 249)
• Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study (2020 · Cancer Research · 被引 133)
• The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab (2021 · Cancers · 被引 111)
• The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer (2018 · Scientific Reports · 被引 56)